Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856413 | 0.88 | MAOA (0.47) | MAOBMAOAL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL22794821 | 0.88 | KDM4E (0.46) | MAOBMAOAHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL23560476 | 0.86 | MAOB (0.47) | MAOBMAOAHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL6672865 | 0.85 | TPSAB1 (0.43) | MAOBMAOAHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL25109335 | 0.84 | MAOA (0.43) | MAOBMAOAHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL19567594 | 0.83 | USP2 (0.51) | MAOBMAOAHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL156068 | 0.83 | ADRB1 (0.47) | MAOBHRH3L3MBTL3L3MBTL1HTR7 | |
| SCHEMBL7914429 | 0.83 | SLC6A2 (0.48) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL23568275 | 0.83 | MAOA (0.43) | MAOBMAOAHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL23806804 | 0.83 | ALDH1A1 (0.40) | MAOBMAOAHRH3L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAOB 2743/4885MAOA 2771/4885HRH3 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.